Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

ASX Announcements

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Nov 15, 2023
Removal from Official List
Nov 14, 2023
Change in substantial holding
Nov 13, 2023
Suspension from Official List
Nov 8, 2023
Change in substantial holding
Nov 3, 2023
Notice of Annual General Meeting/Proxy Form
Nov 2, 2023
Preliminary update from ongoing Phase 2 Study of Paxalisib
Oct 31, 2023
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 31, 2023
Kazia announces short term unsecured Promissory Note
Oct 31, 2023
Proposed issue of securities - KZA
Oct 27, 2023
Kazia SEC Form 20-F
rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 19
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement